Oral Estradiol in Adults 65 and Older: Off-Label Use, Risks, and Clinical Guidance

What Makes Oral Estradiol Use in Patients 65+ Considered Off-Label?

The FDA approved oral estradiol (available as Estrace and generics) for the treatment of moderate-to-severe vasomotor symptoms and vulvovaginal atrophy associated with menopause, as well as for hypoestrogenism from hypogonadism, castration, or primary ovarian insufficiency [1]. The label does not list an upper age boundary. Despite that, the geriatric prescribing community widely categorizes new initiation in patients 65 and older as off-label because key safety data, particularly from the Women's Health Initiative (WHI), shifted clinical consensus against systemic oral estrogen in older postmenopausal women.

The Regulatory Gap Versus Clinical Reality

FDA labeling reflects data from trials that enrolled predominantly women in their 50s. The WHI enrolled women between 50 and 79, but the mean age at enrollment was 63.3 years, and the subgroup 65 and older drove most of the adverse-event signal [2]. That statistical concentration of harm in older enrollees is what separates approved-on-paper from guideline-supported-in-practice.

What "Off-Label" Means Clinically

Off-label does not mean prohibited. Physicians may legally prescribe any approved drug for uses outside the label when clinical judgment supports it. The off-label designation here signals that standard-of-care guidelines from the North American Menopause Society (NAMS), the Endocrine Society, and the American College of Obstetricians and Gynecologists (ACOG) do not recommend routine new initiation of systemic oral estrogen in women over 60 or more than 10 years past the final menstrual period [3].

Cardiovascular and Thromboembolic Risks in the Geriatric Population

Cardiovascular risk is the single largest safety concern driving the off-label classification. Oral estradiol undergoes first-pass hepatic metabolism, which raises clotting-factor synthesis, C-reactive protein, and triglyceride levels in ways that transdermal delivery largely avoids [4].

Venous Thromboembolism

The WHI hormone therapy trial (N=16,608 combined arm) reported a hazard ratio of 2.06 for deep-vein thrombosis in women on oral conjugated equine estrogen (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) vs. Placebo [2]. Absolute risk was 3.5 vs. 1.7 events per 1,000 person-years. In the estrogen-alone arm (women with prior hysterectomy), the hazard ratio for VTE was 1.32. Both hazard ratios were higher in the 65-to-79-year-old stratum than in women under 60.

Stroke

The WHI also recorded a statistically significant increase in ischemic stroke: hazard ratio 1.41 in the combined arm and 1.39 in the estrogen-alone arm [2]. Because baseline stroke risk roughly doubles every decade after age 55, the absolute excess attributable to oral estrogen grows substantially in a 70-year-old compared with a 55-year-old. A meta-analysis in BMJ (N=approximately 900,000 women, 2019) confirmed that oral, but not transdermal, estrogen was associated with elevated stroke risk, with an incidence rate ratio of 1.58 for oral preparations [5].

Coronary Heart Disease

The WHI combined arm showed a non-significant trend toward increased coronary heart disease in the overall cohort (hazard ratio 1.24), with the effect concentrated in women who were more than 10 years past menopause at enrollment [2]. This finding anchors the "timing hypothesis," which holds that estrogen started within 10 years of menopause may be cardioprotective while late initiation may be harmful.

Cognitive Effects and Dementia Risk

The WHI Memory Study

The WHI Memory Study (WHIMS, N=4,532 women aged 65 to 79) found that combined oral estrogen-plus-progestin therapy doubled the risk of probable dementia compared with placebo: hazard ratio 2.05 (95% CI 1.21 to 3.48) over a mean of 4.2 years [6]. The estrogen-alone arm showed a non-significant trend in the same direction (hazard ratio 1.49). These findings remain the primary reason geriatric specialists are reluctant to start oral systemic estrogen in women 65 and older for cognitive preservation.

The Timing Hypothesis Applied to Cognition

Observational data suggest a "critical window" in which initiating estrogen close to menopause may reduce dementia risk, while late initiation may increase it. The Cache County Study (N=1,357) reported that women who used hormone therapy within 5 years of menopause onset had a relative risk of 0.59 for Alzheimer disease, but women who started more than 15 years after menopause showed no protective effect [7]. Oral estradiol initiated at age 65 or older falls outside this protective window for most patients.

Current Guidance on Cognition

The 2022 NAMS position statement states: "Hormone therapy should not be prescribed solely for the purpose of preventing cognitive decline or dementia." [3] This applies to all routes of administration but is particularly relevant to oral formulations given the WHIMS data.

Breast Cancer Considerations

Breast cancer risk from estrogen therapy depends on duration of use, progestogen co-administration, and likely formulation.

Combined vs. Estrogen-Alone Data

The WHI combined arm reported a hazard ratio of 1.26 for invasive breast cancer after 5.6 years of use [2]. The estrogen-alone arm (mean 7.1 years) showed a hazard ratio of 0.77, actually suggesting a lower risk with unopposed estrogen in hysterectomized women, though this finding is mechanistically debated. A Lancet Collaboration analysis (2019, N=108,647 breast cancer cases) found that current use of combined estrogen-progestogen preparations was associated with a relative risk of approximately 2.0 after 10 years, while estrogen-only preparations showed a relative risk of approximately 1.3 after 10 years [8].

Practical Implication for Geriatric Patients

Women aged 65 and older who have been without hormone therapy for many years have baseline breast cancer risk well above the general population simply due to age. Adding oral combined HRT amplifies that baseline risk. This is a core reason NAMS and ACOG recommend that when systemic therapy is truly indicated in older women, the shortest duration and lowest effective dose should be used [3].

Bone Health: One Area Where Evidence Supports Estrogen in Older Women

Estrogen therapy does maintain bone mineral density (BMD) and reduces fracture risk in postmenopausal women, and this effect is one context in which a clinician might still consider oral estradiol off-label in a patient 65 or older.

WHI Fracture Data

The WHI combined arm showed a statistically significant reduction in hip fracture: hazard ratio 0.67 (95% CI 0.47 to 0.96) [2]. The estrogen-alone arm showed a similar result (hazard ratio 0.61). These are meaningful reductions, but licensed bone-specific therapies, including alendronate (FDA-approved for postmenopausal osteoporosis at 70 mg weekly), zoledronic acid (5 mg IV annually), and denosumab (60 mg subcutaneously every 6 months), now carry a more favorable risk-to-benefit profile for fracture prevention in patients 65 and older than systemic oral estrogen [9].

When Estradiol May Still Apply for Bone

A narrow patient subgroup might justify oral estradiol for bone protection in older women: those with intolerance or contraindication to all bisphosphonates, RANK-L inhibitors, and anabolic agents, combined with persistent vasomotor symptoms. Even in this context, transdermal estradiol is preferable to oral because it avoids the clotting-factor stimulation described above.

Genitourinary Syndrome of Menopause: The Strongest Off-Label Case in This Age Group

Genitourinary syndrome of menopause (GSM) including vaginal dryness, dyspareunia, and recurrent urinary tract infections, is present in up to 50% of postmenopausal women and frequently worsens with age [10]. Low-dose vaginal estradiol is FDA-approved specifically for GSM and is the preferred first-line treatment. Oral estradiol is sometimes used off-label for GSM in women 65 and older when vaginal application is not tolerated or when concomitant systemic symptoms justify systemic therapy.

Systemic vs. Local for GSM

The ACOG Practice Bulletin No. 141 (reaffirmed 2022) states: "Low-dose vaginal estrogen is effective for genitourinary syndrome of menopause and is associated with minimal systemic absorption, making it a preferred option for women who have contraindications to systemic hormone therapy." [11] Oral estradiol exposes the patient to systemic hormone levels far exceeding what vaginal preparations deliver. For isolated GSM in a 70-year-old woman, the risk profile of oral estradiol is not justified.

Pharmacokinetics: Why Age Amplifies Oral Estradiol Exposure

Oral estradiol is absorbed in the small intestine and undergoes extensive first-pass hepatic conversion to estrone and estrone sulfate. In women under 55, hepatic metabolism is relatively efficient. In women 65 and older, several pharmacokinetic changes alter this:

Age-Related PK Changes

1. Reduced hepatic blood flow (decreases approximately 40% between age 25 and 75) slows first-pass metabolism, increasing systemic estradiol bioavailability.
2. Decreased albumin and sex hormone-binding globulin (SHBG) in some elderly women increases the free estradiol fraction.
3. Reduced renal clearance of estrone sulfate prolongs circulating estrogen metabolite half-lives.
4. Body composition shifts toward higher fat mass, which serves as an estrogen storage depot and extends effective hormone exposure beyond what a steady-state serum level implies.

These changes mean that a 0.5 mg oral estradiol dose in a 70-year-old woman may deliver effective systemic exposure closer to a 1 mg dose in a 50-year-old. Clinicians should start at the lowest available dose and reassess serum estradiol levels (target: 20 to 60 pg/mL for symptom control, generally staying below 100 pg/mL to minimize risk) at 8 to 12 weeks after initiation.

Dosing Considerations When Oral Estradiol Is Prescribed Off-Label in Patients 65+

Starting Doses

Standard commercial oral estradiol tablets are available as 0.5 mg, 1 mg, and 2 mg. In geriatric off-label use, 0.5 mg per day is the recommended starting point. Compounding pharmacies can prepare 0.25 mg doses when further titration is needed, though compounded formulations lack FDA-approved manufacturing oversight.

Progestogen Requirements

Any patient with an intact uterus requires concurrent progestogen therapy to prevent endometrial hyperplasia and endometrial cancer. Micronized progesterone (Prometrium) at 100 mg daily (continuous) or 200 mg for 12 days per cycle (sequential) is the preferred agent in older women because it does not appear to add the same VTE or stroke risk as synthetic progestogens like medroxyprogesterone acetate, according to the E3N cohort study (N=80,377) [12].

Monitoring Schedule

• Baseline: complete metabolic panel, lipid panel, blood pressure, breast exam, mammogram, and pelvic exam if uterus intact.
• 8 to 12 weeks: serum estradiol and estrone levels, blood pressure, any new symptom review.
• Every 6 months: symptom reassessment and risk-benefit discussion with the patient.
• Annually: lipid panel, mammogram (if not already scheduled), and documented decision to continue or taper.

Contraindications Particularly Relevant in the Geriatric Age Group

Absolute contraindications to oral estradiol that become increasingly common with age include:

• History of VTE or known thrombophilia (Factor V Leiden mutation, prothrombin gene mutation)
• Active or recent arterial thromboembolic event (stroke, myocardial infarction within 12 months)
• Estrogen-receptor-positive breast cancer (personal history or active disease)
• Unexplained abnormal uterine bleeding pending evaluation
• Active liver disease or cholestatic hepatic impairment
• Known or suspected endometrial cancer [1]

The prevalence of each of these conditions rises with age. Clinicians should review the full medication list for drug interactions: oral estradiol induces CYP3A4 and may reduce the efficacy of tamoxifen; it also interacts with anticoagulants, thyroid replacement, and certain antiepileptics.

Alternatives to Oral Estradiol in Patients 65 and Older

When systemic estrogen therapy is genuinely indicated in a 65-plus patient (for example, severe vasomotor symptoms unresponsive to non-hormonal options), transdermal estradiol patches or gels are preferred over oral tablets.

Why Transdermal Is Preferred

Transdermal estradiol bypasses hepatic first-pass metabolism, producing negligible increases in clotting factors, C-reactive protein, and triglycerides [4]. The ESTHER study (N=881 cases, case-control) found that transdermal estradiol was not associated with VTE risk (OR 0.9, 95% CI 0.5 to 1.6), while oral estrogen carried an OR of 3.5 (95% CI 1.8 to 6.8) [13]. Transdermal patches delivering 0.025 mg/day to 0.05 mg/day represent the most evidence-supported systemic option in older women.

Non-Hormonal Options for Vasomotor Symptoms

The FDA approved fezolinetant (Veozah, 45 mg daily), a neurokinin B receptor antagonist, in May 2023 specifically for moderate-to-severe menopausal vasomotor symptoms. It carries no estrogen-related risks and is a reasonable alternative for women 65 and older who are not candidates for any hormone therapy [14]. Paroxetine 7.5 mg (Brisdelle) holds the only FDA approval among SSRIs for this indication.

Summary of Risk-Benefit Framework for Oral Estradiol in Patients 65+

Before prescribing oral estradiol off-label to a patient aged 65 or older, the prescribing clinician should confirm:

1. Non-hormonal and transdermal options have been tried and failed or are contraindicated.
2. The patient has a documented indication (vasomotor symptoms, hypogonadism, specific bone health scenario as above) that is affecting quality of life or carries measurable clinical risk if untreated.
3. No absolute contraindications are present.
4. The patient has received a detailed informed-consent discussion covering VTE, stroke, breast cancer, and dementia risks, with the absolute risk numbers from WHI communicated in plain terms.
5. The lowest effective oral dose (starting at 0.5 mg/day) will be used.
6. A re-evaluation date no longer than 6 months from initiation is scheduled and documented.

The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy states: "We suggest that women with premature menopause or early menopause who have no contraindications use HRT at least until the average age of natural menopause (approximately age 51). For women starting HRT after age 60, risks are more likely to outweigh benefits, and non-estrogen therapies are generally preferred." [15]

Serum estradiol levels should remain below 100 pg/mL in patients 65 and older receiving oral therapy. Document the measurement and the clinical rationale at each follow-up visit.